Abiopharma

🔍 Kuriakose Emil (Executive)

Company: Terns Pharmaceuticals, Inc. (TERN)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Sold 200 shares of Common Stock at $39.6 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 51,320.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 955 shares of Common Stock at $38.3586 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 50,365.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
• F2: This sale price represents the weighted average sale price of the shares sold ranging from $39.25 to $39.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
• F3: This sale price represents the weighted average sale price of the shares sold ranging from $38.25 to $38.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.